XTNT (XTNT) COO reports 7,709-share tax-withholding disposition on RSU vesting

Rhea-AI Filing Summary

Xtant Medical Holdings Chief Operating Officer Mark A. Schallenberger reported a tax-related share disposition. On this Form 4, 7,709 shares of common stock at $0.58 per share were withheld by the company to cover tax obligations upon vesting and settlement of restricted stock units. After this withholding, he reports ownership of 663,157 shares of common stock, which includes large blocks of RSU and DSU awards that will vest only if he remains employed through future vesting dates.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Schallenberger Mark A.

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	7,709	$0.58	$4K

Holdings After Transaction: Common Stock — 663,157 shares (Direct)

Footnotes (1)

1. These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards. Includes an aggregate of 523,794 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 22,250 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schallenberger Mark A.

(Last) (First) (Middle)

C/O XTANT MEDICAL HOLDINGS, INC.

664 CRUISER LANE

(Street)

BELGRADE MT 59714

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xtant Medical Holdings, Inc. [ XTNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/15/2026		F(1)		7,709(1)	D	$0.58	663,157(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were withheld by the Issuer to pay tax withholding obligations upon vesting and settlement of restricted stock unit awards.

2. Includes an aggregate of 523,794 shares issuable upon vesting and settlement of restricted stock unit (RSU) awards or DSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and 22,250 shares issuable upon vesting and settlement of RSU awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, in each case conditioned upon the Reporting Person remaining an employee of Xtant through the applicable vesting dates.

	/s/ Amy Culbert, attorney-in-fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did XTNT COO Mark Schallenberger report on this Form 4?

Mark Schallenberger reported a tax-withholding disposition of 7,709 XTNT common shares. The issuer withheld these shares at $0.58 each to satisfy tax obligations that arose when restricted stock unit awards vested and settled.

Was the XTNT Form 4 transaction an open-market sale of shares?

The Form 4 describes a tax-withholding disposition, not an open-market sale. Shares were withheld by Xtant Medical Holdings to cover tax liabilities tied to vesting restricted stock units, rather than being sold by the executive on the open market.

How many XTNT shares does Mark Schallenberger report owning after this transaction?

After the tax-withholding transaction, Mark Schallenberger reports ownership of 663,157 shares of Xtant Medical common stock. This figure includes shares issuable upon vesting and settlement of RSU and DSU awards under the company’s equity incentive plans.

What equity awards are included in Mark Schallenberger’s reported XTNT holdings?

His reported holdings include 523,794 shares issuable upon vesting and settlement of RSU or DSU awards under the 2023 Equity Incentive Plan and 22,250 shares issuable under the 2018 Equity Incentive Plan, all conditioned on continued employment through applicable vesting dates.

What does transaction code F mean in the XTNT Form 4 filing?

Transaction code F indicates payment of exercise price or tax liability by delivering securities. In this XTNT filing, it reflects the issuer withholding 7,709 common shares to satisfy tax withholding obligations when restricted stock unit awards vested and settled.

How does the XTNT Form 4 describe the nature of the share disposition?

The XTNT Form 4 labels the event as a tax-withholding disposition in common stock. Shares were withheld by the issuer to meet tax obligations triggered by the vesting and settlement of restricted stock unit awards previously granted to the reporting person.